GlassScriptPhysician profile
Panchali Khanna
NPI 1477676286
$1,130.29
in general payments reported to CMS, 2019-2025
23 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $232 · 2021: $247 · 2022: $237 · 2023: $209 · 2024: $59.34 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $155.44 | 2020-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $130.90 | 2020-2022 | |
| Dexcom, INC. | $110.77 | 2020-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $96.35 | 2022-2023 | Omnipod |
| Ascendis Pharma Endocrinology INC | $67.09 | 2025 | Yorvipath |
| Radius Health, INC. | $65.70 | 2021-2024 | |
| Amgen INC. | $56.81 | 2020-2025 | Tepezza |
| Horizon Therapeutics Plc | $49.82 | 2022-2023 | Tepezza |
| Mannkind Corporation | $48.22 | 2022 | |
| Kyowa Kirin, INC. | $38.85 | 2022-2023 | Crysvita |
| Xeris Pharmaceuticals, INC. | $37.03 | 2022-2025 | Recorlev |
| Novo Nordisk INC | $35.04 | 2021-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $31.85 | 2021 | |
| Tandem Diabetes Care, INC. | $24.39 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $24.22 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $23.39 | 2022 | |
| Eusa Pharma (US) LLC | $23.39 | 2022 | |
| Averitas Pharma INC. | $23.07 | 2023 | Qutenza |
| Alexion Pharmaceuticals, INC. | $22.88 | 2023 | Strensiq |
| Ipsen Biopharmaceuticals, INC | $17.59 | 2021 | |
| Amryt Pharma Holdings LTD | $16.05 | 2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $16.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Panchali Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.